Akorn gets slammed, Henry Schein makes a deal, Merck snags double upgrade

Let’s check out the Yahoo Finance charts of the day.

Akorn (AKRX): Shares are tumbling here.  It’s bad news for the generic drugmaker, as Germany’s Fresenius is ditching its plan to buy Akorn following allegations of breaches of FDA data integrity rules.

Henry Schein (HSIC): Shares climbing in early trade. The health care products maker is going to spin off and merge its animal health business with startup Vets First Choice, an online platform for veterinarians.

Merck (MRK): Rounding out our third health care related stock here, Merck shares are rallying following a rare double-upgrade by Goldman to Conviction Buy, citing its Keytruda lung cancer breakthrough.

For more on today’s big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

What to read next